Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2014 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics Reports 2013 Financial Results

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} 2013 Financial Highlights ...
February 07, 2014 12:14 ET | Source: Addex Therapeutics

Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 7 February 2014 -...
November 04, 2013 01:00 ET | Source: Addex Therapeutics

Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva,...
October 29, 2013 02:00 ET | Source: Addex Therapeutics

Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} On track to report top line results end of...
October 03, 2013 01:00 ET | Source: Addex Therapeutics

Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 3 October 2013 - Addex...
September 17, 2013 01:05 ET | Source: Addex Therapeutics

Addex Therapeutics First Half 2013 Financial Results

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} ...
September 04, 2013 01:00 ET | Source: Addex Therapeutics

Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 4 September 2013 - Addex...
August 09, 2013 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics raises CHF3.2 million in a Private Placement to International Institutional Investors

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Cash runway extended to end of 2014 Geneva,...
May 31, 2013 12:03 ET | Source: Addex Therapeutics

Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 31 May 2013 - Addex Therapeutics...
May 28, 2013 01:00 ET | Source: Addex Therapeutics

Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Company intends to restructure the organization and...